MLYS - Company ID 0001933414
The table below shows Mineralys Therapeutics, Inc.'s balance sheet line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash & equivalents | $172.92M | $114.09M | $49.30M |
| Short-term investments | - | - | - |
| Receivables | - | - | - |
| Inventory | - | - | - |
| Total current assets | $661.39M | $205.35M | $249.10M |
| Property, plant & equipment | $38.00K | $53.00K | - |
| Goodwill | - | - | - |
| Total assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $661.81M |
| $205.90M |
| $251.64M |
| Accounts payable | $2.02M | $479.00K | $601.00K |
| Total current liabilities | $15.11M | $14.65M | $10.48M |
| Long-term debt | - | - | - |
| Total liabilities | - | - | - |
| Retained earnings | -$457.17M | -$302.52M | -$124.71M |
| Total equity | $646.69M | $191.26M | $241.15M |